Home
About Us
Information & Guidelines
Article Processing Charges
Open Access Policy
Terms and Conditions
Privacy Policy
Information For Authors
Information Editorial Board
Contact Us
FAQ
Paper Submission Guideline
Register
Login
Submit Now
Vol - 28, Issue - 08
Full-Text PDF
About the Journal
Download
[This article belongs to Volume - 28, Issue - 08]
International Medical Journal
Journal ID
:
IMJ-03-09-2021-917
Total View
:
437
Title
:
The Economic Burden of Non-Small Cell Lung Cancer Epidermal Growth Factor Receptor Mutation Positive in Indonesia
Abstract
: <p>Patients with NSCLC EGFR mutations are patients with advanced stage (stage IIIb/IV) who use targeted therapy as the main therapy such as the Tyrosine Kinase Inhibitors/TKIs (afatinib, gefitinib and erlotinib), the number of treatments received by the patient and the worsening disease prognosis can impact on the economic burden of patients and the Government. This study aims to determine the economic impact of Non-Small Cell Lung Cancer with EGFR mutations in Indonesia. This research is a retrospective observational study with a cross sectional research design that uses the perspective of health provider (health care facilities) and societal (community) conducted at Dr Sardjito Hospital Yogyakarta and Dr Kariadi Hospital Semarang, Indonesia. The results showed that the unit cost of therapy in Non-Small Cell Lung Cancer patients with EGFR mutations using afatinib therapy was Rp. 120,881,289, - and in gefitinib that is Rp. 90.750.186,-. With an average direct medical cost of Rp. 189,699, - and an indirect cost of Rp. 2.250,700.</p>
Download Info
×
Paper Access Key
Access Key
Submit
No Access Key (
Request for Download
)
Name
Email
Country
Send Request
Our Certificates
Guidelines
Information For Authors
Information Editorial Board
FAQ
Further Information
Article Processing Charges
Open Access Policy
Terms and Conditions
Privacy Policy
//